NCT01802060

Brief Summary

This study will examine the performance of the Persona assays in identifying the time when risk of pregnancy is highest by comparing results to ultrasound observed ovulation and other indices of ovulation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2013

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 29, 2013

Completed
3 days until next milestone

Study Start

First participant enrolled

February 1, 2013

Completed
28 days until next milestone

First Posted

Study publicly available on registry

March 1, 2013

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2013

Completed
Last Updated

December 2, 2014

Status Verified

November 1, 2014

Enrollment Period

9 months

First QC Date

January 29, 2013

Last Update Submit

November 27, 2014

Conditions

Keywords

PersonaE3GLHovulation

Outcome Measures

Primary Outcomes (1)

  • Ultrasound

    Accuracy of the LH urine assay contained within PERSONA at predicting ovulation, by comparing the day of the LH surge with ultrasound observed ovulation

    Participants will be followed for one menstrual cycle, anticipated average of four weeks.

Secondary Outcomes (2)

  • Quantitative determination of urinary and serum levels of LH and E3G

    Participants will be followed one menstrual cycle, an anticipated four weeks

  • Volunteer recorded BBT and cervical secretion observations.

    Participants will be followed for one menstrual cycle, an anticipated four weeks

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

General Public

You may qualify if:

  • Female
  • Aged 18 - 40 years
  • Menstrual cycle length between 23 and 35 days
  • Had two natural cycles prior to study participation
  • Using non-hormonal contraception to avoid pregnancy OR abstaining from intercourse for the last three months and the present cycle
  • N.B: Non hormonal contraception includes barrier methods such as male and female condoms, diaphragms or caps, non-hormonal intra-uterine devices such as coils, male and female sterilisation or natural family planning

You may not qualify if:

  • Unwilling to provide written informed consent to participate in the study or comply with study procedures
  • Pregnant
  • Breastfeeding
  • Has menopausal symptoms such as night sweats or hot flushes
  • Using any hormonal treatments e.g. hormonal contraception, fertility treatments and hormone replacement therapy (except thyroxin)
  • Taking antibiotics (based on decision by principle investigator)
  • Has a diagnosis of polycystic ovarian syndrome (PCOS)
  • Has impaired liver or kidney function
  • Intending to use PERSONA as a contraceptive during the study period
  • Contraindications to frequent blood sampling e.g. anaemia, hypotonia and blood clotting diseases
  • Contraindications to frequent ultrasound examinations e.g. morbid obesity and recent abdominal surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Green-ivf, Rheydter Strasse 143, Grevenboich

Düsseldorf, 41515, Germany

Location

Related Publications (2)

  • Gnoth C, Roos J, Broomhead D, Schiffner J, Godehardt E, Freundl G, Johnson S. Antimullerian hormone levels and numbers and sizes of antral follicles in regularly menstruating women of reproductive age referenced to true ovulation day. Fertil Steril. 2015 Dec;104(6):1535-43.e1-4. doi: 10.1016/j.fertnstert.2015.08.027. Epub 2015 Sep 15.

  • Johnson S, Weddell S, Godbert S, Freundl G, Roos J, Gnoth C. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day. Clin Chem Lab Med. 2015 Jun;53(7):1099-108. doi: 10.1515/cclm-2014-1087.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Urine samples Serum samples

Study Officials

  • Christian Gnoth, Dr

    Green-ivf, Rheydter Strasse 143

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 29, 2013

First Posted

March 1, 2013

Study Start

February 1, 2013

Primary Completion

November 1, 2013

Study Completion

November 1, 2013

Last Updated

December 2, 2014

Record last verified: 2014-11

Locations